Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors

• Published in: Journal for immunotherapy of cancer Vol. 11; no. 1; p. e006136
• Main Authors: Lemech, Charlotte, Dredge, Keith, Bampton, Darryn, Hammond, Edward, Clouston, Andrew, Waterhouse, Nigel J, Stanley, Amanda C, Leveque-El Mouttie, Lucie, Chojnowski, Grace M, Haydon, Andrew, Pavlakis, Nick, Burge, Matthew, Brown, Michael P, Goldstein, David
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd 01.01.2023; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Original research
• Subjects: Adenocarcinoma - pathology; Angiogenesis Inhibitors - therapeutic use; Antibodies; Anticoagulants; Biomarkers; Cancer; Cancer therapies; Chemokine CXCL10; Clinical/Translational Cancer Immunotherapy; Colorectal cancer; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - genetics; Colorectal Neoplasms - pathology; Drug dosages; Drug Therapy, Combination; FDA approval; Humans; Immunomodulation; Immunotherapy; Ligands; Lymphocyte Activation; Metastasis; Microsatellite Repeats; Monoclonal antibodies; Nivolumab - pharmacology; Nivolumab - therapeutic use; Pancreatic cancer; Pancreatic Neoplasms; Radiation; Targeted cancer therapy; Toll-Like Receptor 9; Tumors; Australia; New South Wales Australia; Drug Therapy, Combination; Immunomodulation; Lymphocyte Activation; Immunotherapy

BackgroundPixatimod is a unique activator of the Toll-like Receptor 9 pathway. This phase I trial evaluated safety, efficacy and pharmacodynamics of pixatimod and PD-1 inhibitor nivolumab in immunologically cold cancers.Methods3+3 dose escalation with microsatellite stable metastatic colorectal canc...